ALTO-101 Receives FDA Fast Track for CIAS Treatment

Alto Neuroscience has received FDA Fast Track designation for ALTO-101, a potential new treatment for the cognitive difficulties—like poor memory and focus—that millions of schizophrenia patients experience, for which there are currently no approved options.